Brief: Brickell Biotech Announces Sale Of Sofpironium Bromide To Botanix Pharmaceuticals

Fresh Tracks Therapeutics

03/05/2022 21:45

May 3 (Reuters) - Brickell Biotech Inc  BBI.O :
    * BRICKELL BIOTECH ANNOUNCES SALE OF SOFPIRONIUM BROMIDE TO
BOTANIX PHARMACEUTICALS
    * BRICKELL BIOTECH INC - BOTANIX HAS ACQUIRED FROM BRICKELL
ALL
ASSETS PRIMARILY RELATED TO SOFPIRONIUM BROMIDE
    * BRICKELL BIOTECH INC - BRICKELL WILL RECEIVE UPFRONT AND
POTENTIAL NEAR-TERM REGULATORY MILESTONE PAYMENTS OVER NEXT 18
MONTHS OF UP TO $9 MILLION
    * BRICKELL BIOTECH INC - BRICKELL ALSO IS ELIGIBLE TO
RECEIVE
ADDITIONAL SUCCESS-BASED REGULATORY AND SALES MILESTONE PAYMENTS
OF UP TO $168 MILLION
    * BRICKELL BIOTECH INC - BOTANIX WILL BE RESPONSIBLE FOR ALL
FURTHER RESEARCH, DEVELOPMENT, AND COMMERCIALIZATION OF
SOFPIRONIUM BROMIDE GLOBALLY

Source text for Eikon:  ID:nGNX1SJLbx 
Further company coverage:  BBI.O 

 ((Reuters.Briefs@thomsonreuters.com;))